Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-05T04:23:14.214Z Has data issue: false hasContentIssue false
  • English
  • Français

Sertraline in the treatment of panic disorder

A multi-site, double-blind, placebo-controlled, fixed-dose investigation

Published online by Cambridge University Press:  03 January 2018

Peter D. Londborg ,
Robert Wolkow ,
Ward T. Smith ,
Eugene Duboff ,
Donald England ,
James Ferguson ,
Murray Rosenthal  and
Charles Weise
Peter D. Londborg*
Affiliation:
Summit Research Network, Seattle, Washington, USA
Robert Wolkow
Affiliation:
Pfizer Inc., New York, USA
Ward T. Smith
Affiliation:
Summit Research Network, Portland, Oregon, USA
Eugene Duboff
Affiliation:
Center for Behavioral Medicine, Denver, Colorado, USA
Donald England
Affiliation:
Peacehealth Medical Group, Eugene, Oregon, USA
James Ferguson
Affiliation:
Pharmacology Research Corporation, Salt Lake City, Utah, USA
Murray Rosenthal
Affiliation:
Behavioral Medical Research, San Diego, California, USA
Charles Weise
Affiliation:
Charleston, West Virginia, USA
*
Dr P. Londborg, Summit Research Network, 901 Boren Avenue, Suite 1800, Seattle, WA, USA 98104. Fax: 206 624 6975
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

This study compared the efficacy and safety of sertraline to placebo in treating panic disorder.

Method

178 out-patients with panic disorder who exhibited at least four panic attacks during the four weeks prior to screening and three during the two weeks of lead-in were randomly assigned to 12 weeks of double-blind treatment with sertraline (50, 100 or 200 mg) or placebo.

Results

Sertraline was superior to placebo in reducing the number of panic attacks, situational attacks, unexpected attacks, limited symptom attacks, and time spent worrying (all P < 0.01) and the Hamilton Anxiety Scale (P < 0.05), although Clinical Global Impression (Improvement) did not significantly differentiate groups at 12 weeks and at end-point. No serious adverse events were associated with sertraline. No dose relationship was found for adverse events; overall drop-out rates were not different for sertraline or placebo, although more sertraline-treated subjects discontinued for adverse events, typically early in the study. Only dry mouth and ejaculation failure (primarily ejaculation delay) were associated significantly with sertraline. Conclusions Sertraline was effective and safe in reducing panic attacks. Higher doses were no more effective than the 50 mg dose.

Type
Papers
Information
The British Journal of Psychiatry , Volume 173 , Issue 1 , July 1998 , pp. 54 - 60
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Declaration of interest

R.W. is a Senior Associate Medical Director at Pfizer Inc.

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington. DC: APA.Google Scholar
Black, D. W. Werner, R. Bowers, W. et al (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44–50.CrossRefGoogle ScholarPubMed
Cassano, G. B. Toni, C. Petracca, A. et al (1994) Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. Europea. Neuropsychopharmacology, 4, 47–53.CrossRefGoogle ScholarPubMed
Den-Boer, J. A. Westenberg, H. G. De Leeuw, A. S. et al (1995) Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. International Clinical Psychopharmacology, 4, 47–52.CrossRefGoogle Scholar
Greist, J. H. Chouinard, G. Duboff, E. et al (1995) Double-blind parallel comparison of three doses of sertraline and placebo in outpatients with obsessive compulsive disorder. Archives of General Psychiatry, 52, 289–295.CrossRefGoogle ScholarPubMed
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub (ADM). Rockville, MD: National Institute for Mental Health.Google Scholar
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.CrossRefGoogle ScholarPubMed
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social Clinical Psychology, 6, 278–296.CrossRefGoogle ScholarPubMed
Hoehn-Saric, R. McLeod, D. R. & Hipsley, P. A. (1993) Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology, 13, 321–326.CrossRefGoogle ScholarPubMed
Louie, A. K. Lewis, T. B. & Lannon, R. A. (1993) Use of low-dose fluoxetine in major depression and panic disorder. Journal of Clinical Psychiatry, 54, 435–438.Google ScholarPubMed
Nagy, L. M. Morgan, C. A. III Southwick, S. M. et al (1993) Open prospective trial of fluoxetine for posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 13, 107–113.CrossRefGoogle ScholarPubMed
Noyes, R. Jr Garvey, M. J. Cook, B. L. et al (1989) Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. Journal of Clinical Psychiatry, 50, 63–69.Google ScholarPubMed
Oehrberg, S. Christiansen, P. E. Behnke, K. et al (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374–379.CrossRefGoogle ScholarPubMed
Pecknold, J. C. (1993) Discontinuation reactions to alprazolam in panic disorder. Conference on Panic and Anxiety: A Decade of Progress (1990, Geneva. Switzerland). Journal of Psychiatric Research, 27 (suppl. 1), 155–170.CrossRefGoogle Scholar
Pecknold, J. C. Luthe, L. Iny, L. et al (1995) Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. Psychiatry Neuroscience, 20, 193–198.Google ScholarPubMed
Pounds, R. (1992) A review of the medical and social consequences of generalized anxiety disorder and panic disorder. Journal of the Louisiana State Medical Society, 144, 479–483.Google ScholarPubMed
Rosenberg, R. (1993) Drug treatment of panic disorder. Pharmacology and Toxicology, 72, 344–353.CrossRefGoogle ScholarPubMed
Salzman, C. (1993) Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse (Review). Journal of Psychiatric Research, 27 (suppl. 1), 97–100.CrossRefGoogle Scholar
Sheehan, D. V. (1989) Diagnosis and psychiatry: examination of the psychiatric patient. In Comprehensive Textbook of Psychiatry (5th edn) (eds Kaplan, H. I. & Sadock, B. J.). Baltimore, MD: Williams and Wilkins.Google Scholar
Spitzer, R. L. Williams, J. B. W. Gibbons, M. et al (1990) Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press.Google Scholar
Svebak, S. Cameron, A. & Levander, S. (1990) Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side-effects. Journal of Clinical Psychiatry, 51 (suppl.). 14–17, 50–53.Google ScholarPubMed
Wade, A. Lepoto, U. Koponen, H. et al (1997) The effect of citalopram in panic disorder. British Journol of Psychiatry, 170, 549–553.CrossRefGoogle ScholarPubMed
Weinstein, R. S. (1995) Panic disorder. American Family Physician, 52, 1999–2000, 2055–2063. 2067–2068.Google ScholarPubMed
Weissman, M. M. (1988) The epidemiology of panic disorder and agoraphobia. American Psychiatric Press Review of Psychiatry (Vol. 7) (eds Frances, A. J. & Hales, R. E.), pp. 54–66. Washington, DC: American Psychiatric Press.Google Scholar
Wolkow, R. Alderman, J. Johnson, H. et al (1996) Sertraline treatment of children and adolescents with obsessive compulsive disorder or depression. X World Congress of Psychiotry Abstracts, 2, 145.Google Scholar
Yeragani, V. K. Pohl, R. Baton, R. et al (1992) Imipramine-induced jitteriness and decreased serum iron levels. Neuropsychobiology, 25, 8–10.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.